Loading…
Loading…
EQUITY / NASDAQ · XNCM
MiNK Therapeutics, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗12.44 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 12.44 USD · Volume 49,056
681 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Operating profit | -3,216,894 USD | — | — |
| Net income | -3,128,201 USD | — | — |
| Cash and cash equivalents | 8,806,977 USD | — | — |
| Total equity | -14,028,296 USD | — | — |
| Total assets | 9,615,242 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 109/30/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 8,806,977 USD | — | — | 13,360,340 USD | 13,360,340 USD | 9,500,000 USD | 14,281,212 USD | — |
| Net incomeIncome statement | -3,128,201 USD | -5,870,570 USD | -2,742,368 USD | — | -12,494,260 USD | — | -2,887,709 USD | -9,892,157 USD |
| Operating profitIncome statement | -3,216,894 USD | -6,098,681 USD | — | — | -12,642,136 USD | — | -3,183,594 USD | -9,936,677 USD |
| Total assetsBalance sheet | 9,615,242 USD | — | — | 14,238,842 USD | 14,238,842 USD | — | 14,963,665 USD | — |
| Total equityBalance sheet | -14,028,296 USD | — | -12,685,989 USD | -14,227,659 USD | -14,227,659 USD | — | -13,512,982 USD | — |
| Financing cash flowCash flow statement | — | -734,676 USD | — | — | 14,721,897 USD | — | — | 13,546,794 USD |
| Operating cash flowCash flow statement | — | -3,815,409 USD | — | — | -5,925,168 USD | — | — | -3,851,442 USD |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 03/31/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.